Cora Ruhl, MD
Family Medicine · Arkansas City, KSNPI 1013409267
Payments from drug & device makers
Across 244 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$941
- Lilly USA, LLC$598
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$385
- AbbVie$348
- Otsuka America Pharmaceutical, Inc.$218
- Novo Nordisk$213
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,988100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 47 | $941 |
| Lilly USA, LLC | 52 | $598 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $385 |
| AbbVie | 22 | $348 |
| Otsuka America Pharmaceutical, Inc. | 11 | $218 |
| Novo Nordisk | 12 | $213 |
| Merck | 12 | $174 |
| Boehringer Ingelheim | 10 | $157 |
| Idorsia Pharmaceuticals US Inc | 6 | $95 |
| Novartis | 6 | $90 |
| Lundbeck LLC | 4 | $81 |
| GSK | 3 | $60 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $60 |
| Bayer | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $46 |
| Medline Industries LP | 1 | $46 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Abbott | 2 | $37 |
| Amgen | 2 | $34 |
| Pfizer | 2 | $33 |
| Johnson & Johnson | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Bioventus LLC | 1 | $26 |
| Dexcom, Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Smith+Nephew | 1 | $22 |
| Eisai Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Insulet Corporation | 1 | $14 |
| Exact Sciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,988 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 90 | $97,074 |
| Enbrel SureclickEtanercept | 11 | $75,462 |
| OzempicSemaglutide | 71 | $74,803 |
| TrulicityDulaglutide | 70 | $67,719 |
| JardianceEmpagliflozin | 83 | $57,694 |
| FarxigaDapagliflozin Propanediol | 90 | $56,529 |
| XareltoRivaroxaban | 78 | $47,962 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $47,752 |
| EliquisApixaban | 92 | $46,740 |
| Invega SustennaPaliperidone Palmitate | 16 | $39,149 |
| XifaxanRifaximin | 52 | $36,623 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $34,639 |
| MyrbetriqMirabegron | 56 | $28,140 |
| RexultiBrexpiprazole | 19 | $27,898 |
| QuliptaAtogepant | 21 | $23,649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $598 | $164,793160 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $941 | $109,665170 claims |
| Novo NordiskOzempic, Rybelsus | $213 | $93,62789 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $31 | $87,11094 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $157 | $75,901118 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $385 | $52,02281 claims |
| PfizerEliquis | $33 | $46,74092 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $60 | $41,75866 claims |
| AbbVieQulipta, Linzess | $348 | $40,90750 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $218 | $27,89819 claims |
| MerckJanuvia, Belsomra | $174 | $23,60846 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $95 | $6,93615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Arkansas City
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.